Phaseline

Companies › Bisirna Therapeutics (Suzhou)

Bisirna Therapeutics (Suzhou): clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Cardiovascular, Other; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VSA012
Complement system inhibitor
–Phase 1Healthy VolunteersJun 2027
BSA204
LPA antisense oligonucleotide inhibitor
LPAPhase 1DyslipidemiasJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06766929VSA012Phase 1Healthy VolunteersOtherJun 2027
NCT07551505BSA204Phase 1DyslipidemiasCardiovascularJul 2027

Targets

LPA (1)

Companies with the same targets

Amgen Novartis Eli Lilly

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.